Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 6:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: N-0923 Clear all
Completed Phase 3 Interventional Results available

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)

NCT01569464
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • Jasper, Alabama • Gilbert, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

NCT01744496
View directory record Official record
Conditions
Advanced Idiopathic Parkinson's Disease
Interventions
Rotigotine, Placebo
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Gilbert, Arizona • Sunnyvale, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 18, 2026, 6:21 AM EDT
Active, not recruiting Phase 3 Interventional

Infusion of Apomorphine: Long-term Safety Study

NCT02339064
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
apomorphine infusion
Drug
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 18, 2026, 6:21 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Study to Assess Dopamine Receptor Modulation With Rotigotine to Enhance Morphine Analgesia in the Dental Model

NCT02123979
View directory record Official record
Conditions
Post-op Pain
Interventions
Neupro® transdermal patch/placebo
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2015 · Synced Oct 18, 2026, 6:21 AM EDT
Terminated Phase 3 Interventional Results available

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

NCT00519532
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
St. Petersburg, Florida • Salisbury, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.

NCT00594165
View directory record Official record
Conditions
Early-Stage Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
31 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
37
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease

NCT03589066
View directory record Official record
Conditions
Parkinson Disease
Interventions
LY03003
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Hallandale, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease

NCT00594386
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
31 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
37
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 18, 2026, 6:21 AM EDT
Not listed Phase 1 Interventional

A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

NCT02579473
View directory record Official record
Conditions
Parkinson's Disease
Interventions
SER-214
Drug
Lead sponsor
Serina Therapeutics
Industry
Eligibility
40 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Birmingham, Alabama • Hallandale, Florida • Augusta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Irritation and Sensitization Potential of Repeat Applications of Rotigotine Patch

NCT02727205
View directory record Official record
Conditions
Bioequivalence - Irritation and Sensitization Potential of Transdermal Patch
Interventions
Rotigotine Transdermal System
Drug
Lead sponsor
Inflamax Research Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 3 Interventional

A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease

NCT00242008
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Timeline
2004 – 2005
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 18, 2026, 6:21 AM EDT
Terminated Phase 4 Interventional Results available

Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment

NCT02365870
View directory record Official record
Conditions
Anxiety Disorders, Parkinson Disease
Interventions
rotigotine transdermal patch, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 89 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 2 Interventional

Treatment of Parkinson's Disease With a Transdermal Skin Patch

NCT00001931
View directory record Official record
Conditions
Parkinson Disease
Interventions
N-0923
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 18, 2026, 6:21 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause

NCT03728933
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine 1 milligram/24 hours, Rotigotine 2 milligram/24 hours, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
13 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management

NCT03103919
View directory record Official record
Conditions
Parkinson´s Disease
Interventions
Kinesia-ONE™, Kinesia-360™, Rotigotine
Device · Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Fountain Valley, California • Boca Raton, Florida • Winfield, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 18, 2026, 6:21 AM EDT
Withdrawn Phase 4 Interventional

Butrans for Treatment of Restless Legs Syndrome

NCT02138357
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
buprenorphine transdermal delivery system (BTDS), Placebo for BTDS patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 2 Interventional

Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder

NCT05886582
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Rotigotine Transdermal System [Neupro], Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
25 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

NCT02728947
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ROTIGOTINE
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 99 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Long Beach, California • Hallandale, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 4 Interventional Results available

Switching From Oral Dopamine Agonists to Rotigotine

NCT01976871
View directory record Official record
Conditions
Restless Legs Syndrome, Ekbom Syndrome, Willis-Ekbom Disease
Interventions
Rotigotine
Drug
Lead sponsor
John Winkelman, MD, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro

NCT03733561
View directory record Official record
Conditions
Parkinson Disease
Interventions
LY03003, Neupro 4Mg/24Hr Transdermal Patch
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 18, 2026, 6:21 AM EDT
Enrolling by invitation Phase 4 Interventional

Quality Improvement and Practice Based Research in Neurology Using the EMR

NCT02670161
View directory record Official record
Conditions
Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
Interventions
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 100 Years
Enrollment
3,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 3 Interventional

Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome

NCT00135993
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome

NCT01498120
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
13 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Spring Hill, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults.

NCT00464737
View directory record Official record
Conditions
Fibromyalgia Syndrome
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
35
States / cities
Mobile, Alabama • Mesa, Arizona • Peoria, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 18, 2026, 6:21 AM EDT